Amibegron Explained

Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β₃ adrenergic receptor. It is the first orally active β₃ agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.^{[1] [2]}

On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.^[3]

Notes and References

1. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G . 6 . Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders . Neuropsychopharmacology . 33 . 3 . 574–87 . February 2008 . 17460614 . 10.1038/sj.npp.1301424 . free .
2. Overstreet DH, Stemmelin J, Griebel G . Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression . Pharmacology, Biochemistry, and Behavior . 89 . 4 . 623–6 . June 2008 . 18358519 . 10.1016/j.pbb.2008.02.020 . 35026036 .
3. https://archive.today/20110807103952/http://en.sanofi-aventis.com/press/press_releases/2008/ppc_20376.asp Second quarter 2008 results